{"id":"https://openalex.org/W2015953045","doi":"https://doi.org/10.1021/jm00369a010","title":"Antiviral activity of C-5 substituted tubercidin analogs","display_name":"Antiviral activity of C-5 substituted tubercidin analogs","alternate_titles":[],"publication_year":1984,"publication_date":"1984-03-01","ids":{"openalex":"https://openalex.org/W2015953045","doi":"https://doi.org/10.1021/jm00369a010","mag":"2015953045","pmid":"https://pubmed.ncbi.nlm.nih.gov/6699874"},"language":"en","primary_location":{"id":"doi:10.1021/jm00369a010","doi":"https://doi.org/10.1021/jm00369a010","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm00369a010","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2015953045"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058584250","display_name":"Donald E. Bergstrom","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Donald E. Bergstrom","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063029833","display_name":"Alan J. Brattesani","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Alan J. Brattesani","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086615108","display_name":"Mark K. Ogawa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mark K. Ogawa","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058080616","display_name":"P. Anantha Reddy","orcid":"https://orcid.org/0000-0002-3656-1411","observed_orcids":["https://orcid.org/0000-0002-3656-1411"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"P. Anantha Reddy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058901742","display_name":"Michael J. Schweickert","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael J. Schweickert","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038319371","display_name":"Jan M. Balzarini","orcid":"https://orcid.org/0000-0003-2240-3321","observed_orcids":["https://orcid.org/0000-0003-2240-3321","https://orcid.org/0000-0003-1144-1808"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jan Balzarini","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5040662398","display_name":"Erik De Clercq","orcid":"https://orcid.org/0000-0002-2985-8890","observed_orcids":["https://orcid.org/0000-0002-2985-8890"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Erik De Clercq","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":8.275,"has_fulltext":false,"cited_by_count":79,"citation_normalized_percentile":{"value":0.98878656,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"27","issue":"3","first_page":"285","last_page":"292"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T14099","display_name":"Synthesis and Characterization of Heterocyclic Compounds","score":0.28690001368522644,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T14099","display_name":"Synthesis and Characterization of Heterocyclic Compounds","score":0.28690001368522644,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12827","display_name":"Biochemical and Molecular Research","score":0.13439999520778656,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.13199999928474426,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tubercidin","display_name":"tubercidin","score":0.8960000276565552},{"id":"https://openalex.org/keywords/antiviral-activity","display_name":"antiviral activity","score":0.875},{"id":"https://openalex.org/keywords/toyocamycin","display_name":"toyocamycin","score":0.8650000095367432},{"id":"https://openalex.org/keywords/sangivamycin","display_name":"sangivamycin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/rna-viruses","display_name":"RNA viruses","score":0.7570000290870667},{"id":"https://openalex.org/keywords/dna-viruses","display_name":"DNA viruses","score":0.9819999933242798},{"id":"https://openalex.org/keywords/coxsackievirus-b4","display_name":"coxsackievirus B4","score":0.8769999742507935},{"id":"https://openalex.org/keywords/reovirus-type-1","display_name":"reovirus type 1","score":0.9520000219345093},{"id":"https://openalex.org/keywords/parainfluenza-virus-type-3","display_name":"parainfluenza virus type 3","score":0.9890000224113464},{"id":"https://openalex.org/keywords/cytotoxicity","display_name":"cytotoxicity","score":0.7720000147819519},{"id":"https://openalex.org/keywords/structure-activity-relationship","display_name":"structure-activity relationship","score":0.75},{"id":"https://openalex.org/keywords/in-vivo-antiviral-activity","display_name":"in vivo antiviral activity","score":0.6480000019073486}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.7783045768737793},{"id":"https://openalex.org/C2777366897","wikidata":"https://www.wikidata.org/wiki/Q847482","display_name":"HeLa","level":3,"score":0.7739571928977966},{"id":"https://openalex.org/C2776543447","wikidata":"https://www.wikidata.org/wiki/Q28734","display_name":"Nucleoside","level":2,"score":0.7150708436965942},{"id":"https://openalex.org/C2779321679","wikidata":"https://www.wikidata.org/wiki/Q207722","display_name":"Pyrimidine","level":2,"score":0.5416091680526733},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5322171449661255},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.5308479070663452},{"id":"https://openalex.org/C116073593","wikidata":"https://www.wikidata.org/wiki/Q864491","display_name":"Biological activity","level":3,"score":0.5308445692062378},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.5119708776473999},{"id":"https://openalex.org/C89138240","wikidata":"https://www.wikidata.org/wiki/Q3066564","display_name":"Vero cell","level":3,"score":0.5105050802230835},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.46773892641067505},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.4188617169857025},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.3246867060661316},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1736030876636505},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000903","descriptor_name":"Antibiotics, Antineoplastic","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D002522","descriptor_name":"Chlorocebus aethiops","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004267","descriptor_name":"DNA Viruses","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006367","descriptor_name":"HeLa Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011741","descriptor_name":"Pyrimidine Nucleosides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011817","descriptor_name":"Rabbits","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012263","descriptor_name":"Ribonucleosides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D012328","descriptor_name":"RNA Viruses","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D014127","descriptor_name":"Toyocamycin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D014372","descriptor_name":"Tubercidin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D014372","descriptor_name":"Tubercidin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1021/jm00369a010","doi":"https://doi.org/10.1021/jm00369a010","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm00369a010","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:6699874","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/6699874","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2002661874","https://openalex.org/W1980993892","https://openalex.org/W2952169749","https://openalex.org/W2035982103","https://openalex.org/W3156256377","https://openalex.org/W2005846310","https://openalex.org/W2949878569","https://openalex.org/W2002745614","https://openalex.org/W1984574763","https://openalex.org/W2520608854"],"abstract_inverted_index":{"The":[0,72,142],"pyrrolo[2,3-d]pyrimidine":[1],"nucleoside":[2],"antibiotics":[3],"tubercidin,":[4],"toyocamycin,":[5],"and":[6,8,24,36,47,70,85,98,104,123,152,176],"sangivamycin":[7],"the":[9,53,59,63,80,105,130,162,169,177],"synthetic":[10],"analogues":[11,182],"5-chloro-,":[12],"5,6-dichloro-,":[13,69],"5-bromo-,":[14],"6-bromo-,":[15,68],"5,6-dibromo-,":[16],"5-iodo-,":[17],"5-(1-hydroxyethyl)-,":[18],"5-(1-methoxyethyl)-,":[19,84],"(E)-5-(2-bromoethenyl)-,":[20],"(E)-5-(2-cyanoethenyl)-,":[21],"5-(2-buten-1-yl)-,":[22],"5-(3-hydroxypropyl)-,":[23],"5-butyltubercidin":[25],"were":[26,76,87,149],"evaluated":[27],"for":[28,79,109],"their":[29],"antiviral":[30],"properties":[31],"against":[32,58,90,113],"six":[33],"RNA":[34,60],"viruses":[35,39],"three":[37],"DNA":[38],"in":[40,110,118,129],"HeLa":[41],"cell,":[42,46],"primary":[43],"rabbit":[44],"kidney":[45],"Vero":[48],"cell":[49,147],"cultures.":[50],"Most":[51],"of":[52,137,171,179,183],"derivatives":[54,75],"had":[55],"substantial":[56],"activity":[57,65,112],"viruses,":[61],"with":[62],"least":[64],"shown":[66],"by":[67],"5,6-dibromotubercidin.":[71],"C-5":[73,175,180],"substituted":[74,181],"quite":[77],"toxic":[78],"host":[81],"cells.":[82],"5-(1-Hydroxyethyl)-,":[83],"5-(2-buten-1-yl)tubercidin":[86],"more":[88],"selective":[89],"reovirus":[91],"type":[92,96],"1,":[93],"parainfluenza":[94],"virus":[95,100,116],"3":[97],"Coxsackie":[99,114],"B4":[101,115],"than":[102],"tubercidin":[103,184],"5-halotubercidins.":[106],"When":[107],"tested":[108],"vivo":[111],"infection":[117],"newborn":[119],"NMRI":[120],"mice,":[121],"5-(1-hydroxyethyl)-":[122],"5-(1-methoxyethyl)tubercidin":[124],"caused":[125],"a":[126,134],"significant":[127],"decrease":[128],"mortality":[131],"rate":[132],"at":[133,174],"dose":[135],"level":[136],"100":[138],"micrograms":[139],"per":[140],"mouse.":[141],"inhibitory":[143],"effects":[144],"on":[145],"L-1210":[146],"growth":[148],"also":[150],"determined,":[151],"toyocamycin":[153],"(ID50":[154],"=":[155],"0.006":[156],"micrograms/mL)":[157],"was":[158],"found":[159],"to":[160],"be":[161],"most":[163],"active":[164,187],"compound.":[165],"This":[166],"study":[167],"demonstrates":[168],"significance":[170],"structural":[172],"modification":[173],"potential":[178],"as":[185],"biologically":[186],"agents.":[188]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2015953045","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":9},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2016-06-24T00:00:00"}
